SCHEMBL4055488

SCHEMBL4055488

O=C(Nc1cccc(-c2nc3ccc(Br)cc3o2)c1)c1ccccc1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.77
POLB P06746 6/20 0.64
SMN1; SMN2 Q16637 4/20 0.64
KDM4E B2RXH2 4/20 0.64
ALDH1A1 P00352 4/20 0.64
MEN1 O00255 2/20 0.64
KMT2A Q03164 2/20 0.64
DUSP1 P28562 2/20 0.64
GAA P10253 1/20 0.62
RXFP1 Q9HBX9 2/20 0.61
TP53 P04637 4/20 0.59
TLR9 Q9NR96 1/20 0.59
P2RY14 Q15391 1/20 0.58
USP2 O75604 1/20 0.56
PKM P14618 1/20 0.56
HPGD P15428 1/20 0.56
HSD17B10 Q99714 1/20 0.56
LMNA P02545 2/20 0.55
NPSR1 Q6W5P4 1/20 0.55
TSHR P16473 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4057091 0.85 CASP3 (0.68) MAPTPOLBSMN1; SMN2KDM4EALDH1A1
SCHEMBL16291851 0.82 MAPT (0.85) MAPTPOLBSMN1; SMN2KDM4EALDH1A1
SCHEMBL4055885 0.82 KDM4E (0.59) MAPTPOLBSMN1; SMN2KDM4EALDH1A1
SCHEMBL4052971 0.82 LCLAT1 (0.66) MAPTPOLBSMN1; SMN2KDM4EALDH1A1
SCHEMBL4063517 0.81 NPC1 (0.60) MAPTPOLBSMN1; SMN2KDM4EALDH1A1
SCHEMBL26144046 0.80 MAPT (0.77) MAPTPOLBSMN1; SMN2KDM4EALDH1A1
SCHEMBL4051636 0.79 MAPT (0.53) MAPTPOLBSMN1; SMN2KDM4EALDH1A1
SCHEMBL3145506 0.79 TP53 (0.61) MAPTPOLBSMN1; SMN2KDM4EALDH1A1
SCHEMBL6915940 0.79 MAPT (0.61) MAPTPOLBSMN1; SMN2DUSP1RXFP1
Methane SCHEMBL6821818 0.78 MAPT (0.61) MAPTPOLBSMN1; SMN2DUSP1RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B MAPT 4026/4885POLB 783/4885SMN1; SMN2 4289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.